BEST – Biomarker evaluation to support clinical translation for schizophrenia

Psychoses are a group of disorders of extraordinary heterogeneity.


Psychoses describe an extremely heterogeneous group of diseases. As a result, diagnoses, prognoses and treatment decisions for individual patients are challenging. Within the project, biomarker signatures of patients at high risk of schizophrenia and patients with defined psychotic disorders will be optimized. This will be investigated by integrating multimodal patient data and subsequent functional validation of biomarker signatures using patient derived neurons.



Prof. Dr. Hansjürgen Volkmer

Head of Pharma & Biotech